Ecnoglutide
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Hangzhou Sciwind Biosciences Co · Phase 1/2 · Recruiting · Enrollment 126
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| oral ecnoglutide dose 1 | n/r | n/r | n/r | n/r |
| oral ecnoglutide dose 2 | n/r | n/r | n/r | n/r |
| oral ecnoglutide dose 3 | n/r | n/r | n/r | n/r |
| oral ecnoglutide dose 4 | n/r | n/r | n/r | n/r |
| placebo dose 1 | n/r | n/r | n/r | n/r |
| placebo dose 2 | n/r | n/r | n/r | n/r |
Not shown
- oral ecnoglutide dose 1: endpoint not reported
- oral ecnoglutide dose 2: endpoint not reported
- oral ecnoglutide dose 3: endpoint not reported
- oral ecnoglutide dose 4: endpoint not reported
- placebo dose 1: endpoint not reported
- placebo dose 2: endpoint not reported